Systematic review and meta-analysis of randomized controlled trials of antibiotics and antiseptics for preventing infection in people receiving primary total hip and knee prostheses

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6696-6707

  Voigt, Jeffrey ^a   Mosier, Michael ^b   Darouiche, Rabih ^c  

^a Independent Researcher   (United States)

^b WASHBURN UNIVERSITY   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; TOPICAL ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COCHRANE LIBRARY; DATA BASE; EMBASE; HUMAN; INFECTION RATE; MEDLINE; META ANALYSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; BACTERIAL INFECTIONS; HIP REPLACEMENT; KNEE PROSTHESIS; KNEE REPLACEMENT; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBIOTIC PROPHYLAXIS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BACTERIAL INFECTIONS; HUMANS; KNEE PROSTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84946223092     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01331-15     Document Type: Review

References (101)

1. Sorci Miller R. 2008. Increasing incidence of joint replacements burdens healthcare system. http://ezinearticles.com/?Increasing-Incidence-of-Joint-Replacements-Burdens-Healthcare-System&id=1816810. Accessed 26 November 2014.
2. Agency for Healthcare Research and Quality. 2015. HCUPNet 2012 inpatient database: ICD9CMD procedure codes 81.51 (THA) and 81.54 (TKA). http://hcupnet.ahrq.gov/. Accessed on 27 April 2015.
3. Maradit-Kremers H., Crowson CS, Larson D, Jiranek W.A., Berry DJ. 2014. Prevalence of total hip (THA) and total knee (TKA) arthroplasty in the United States. Abstr 2014 Am Assoc Orthop Surg, abstr P057.
4. Berbari EF, Hanssen AD, Duffy M.C., Steckelberg JM, Ilstrup DM, Harmsen WS, Osmon DR 1998. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 27:1247-1254. http://dx.doi.org/10.1086/514991.
5. Hanssen AD, Rand JA 1998. Evaluation and treatment of infection at the site of total hip or knee arthroplasty. J Bone Joint Surgery Am 80: 910-922.
6. Peersman G, Laskin R, Davis J., Peterson M. 2001. Infection in total knee replacement: a retrospective review of 6,489 total knee replacements. Clin Orthop Relat Res 392:15-23. http://dx.doi.org/10.1097/00003086-200111000-00003.
7. SooHoo NF, Lieberman JR, Ko C.Y., Zongmond DS. 2006. Factors predicting complication rates following total knee replacement. J Bone Joint Surg Am 88:480-485. http://dx.doi.org/10.2106/JBJS.E.00629.
8. Anagnostakos K, Schmid NV, Kelm J, Grün U, Jung J. 2009. Classification of hip joint infections. Int J Med Sci 6:227-233.
9. Ong KL, Kurtz SM, Lau E, Bozic K.J., Berry DJ, Parvizi J. 2009. Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty 26:105-109.
10. Kurtz SM, Lau E, Schmier J., Ong KL, Zhoa K, Parvizi J. 2008. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty 23:984-991. http://dx.doi.org/10.1016/j.arth.2007.10.017.
11. Del Pozo J.L., Patel R. 2009. Infection associated with prosthetic joints. N Engl J Med 361:787-794. http://dx.doi.org/10.1056/NEJMcp0905029.
12. Kurtz SM, Ong KL, Lau E, Bozic K.J., Berry D., Parvizi J. 2010. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 468:52-56. http://dx.doi.org/10.1007/s11999-009-1013-5.
13. Fisman DN, Reilly DT, Karchmer A.W., Goldie SJ. 2001. Clinical effectiveness and cost effectiveness of two management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis 32:419-430. http://dx.doi.org/10.1086/318502.
14. Herbert CK, Williams RE, Levy R.S., Barrack RL. 1996. Cost of treating an infected total knee replacement. Clin Orthop Relat Res 331:140-145. http://dx.doi.org/10.1097/00003086-199610000-00019.
15. Jiranek WA, Hanssen AD, Greenwald AS 2006. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am 88:2487-2500. http://dx.doi.org/10.2106/JBJS.E.01126.
16. Sculco TP. 1993. The economic impact of infected total joint arthroplasty. Instr Course Lect 42:349-351.
17. Smith PN, Terweil E, Cahill J., Scarvell J. 2004. A cost-benefit analysis of infection prophylaxis in total joint arthroplasty. J Bone Joint Surg Br 86(Suppl): 465-466.
18. Mangram AJ, Horan TC, Pearson M.L., Silver LC, Jarvis WR. 1999. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Hospital Infect Control Hosp Epidemiol 20:250-278. http://dx.doi.org/10.1086/501620.
19. Darouiche RO, Wall MJ, Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH. 2010. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 362:18-26. http://dx.doi.org/10.1056/NEJMoa0810988.
20. Bratzler DW, Houck PM 2005. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surgery 189:395-404. http://dx.doi.org/10.1016/j.amjsurg.2005.01.015.
21. Scottish Intercollegiate Guidelines Network (SIGN). 2015. Search filters. http://www.sign.ac.uk/methodology/filters.html#random. Accessed 5 May 2015.
22. Glenny A, Song F. 1999. Antimicrobial prophylaxis in total hip replacement: a systematic review. Health Technol Assess 3:1-57.
23. Horan TC, Gaynes RP, Martone W.J., Jarvis WR, Emori TG. 1992. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606-608.
24. AlBuhairan B, Hind D, Hutchinson A. 2008. Antibiotic prophylaxis for wound infections in total joint arthroplasty: a systematic review. J Bone Joint Surg Br 90:915-919. http://dx.doi.org/10.1302/0301-620X.90B7.20498.
25. American Academy of Orthopedic Surgeons. 2015. Information statement 1027: recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthrosplasty. http://www.aaos.org/about/papers/advistmt/1027.asp. Accessed 7 February 2015.
26. Gerding DN. 2004. Clindamycin, cephalosporins, fluoroqunilones, and Clostridium difficile-associated diarrhea: this is an antibiotic resistance problem. Clin Infect Dis 38:646-648. http://dx.doi.org/10.1086/382084.
27. Dancer SJ. 2001. The problem with cephalosporins. J Antimicrob Chemother 48:463-478. http://dx.doi.org/10.1093/jac/48.4.463.
28. Stein BE, Greenbough WB, Mears SC 2012. Management and prevention of recurrent Clostridium difficile infection in patients after total joint arthroplasty: a review. Geriatr Orthop Surg Rehabil 3:157-163. http://dx.doi.org/10.1177/2151458513479023.
29. U.S. Department of Health and Human Services Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 1 March 2015.
30. Engemann J, Carmeli Y, Cosgrove S.E., Fowler VG, Bronstein MZ, Trivette SL, Briggs J.P., Sexton DJ, Kaye KS. 2003. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36:592-598. http://dx.doi.org/10.1086/367653.
31. Bang H, Chiu YL, Memtsoudis S.G., Mandl LA, Della Vale AG, Mushlin AK, Marx RG, Mazumdar M. 2010. Total hip and total knee arthroplasties: trends and disparities revisited. Am J Orthop (Belle Meade NJ) 39: E95-E102.
32. Jämsen E., Nevalainen P, Eskelinen A., Huotari K, Kalilavalkama J, Moilanen T. 2012. Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single center analysis of 7181 primary hip and knee replacements for osteoarthritis. J Bone Joint Surg Am 94:e101. http://dx.doi.org/10.2106/JBJS.J.01935.
33. Bozic KJ, Lau E, Kurtz S., Ong K, Rubash H, Vail T.P., Berry DJ. 2012. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surgery Am 94:794-800. http://dx.doi.org/10.2106/JBJS.K.00072.
34. Namba RS, Inacio MC, Paxton EW 2013. Risk factors associated with deep surgical site infections after primary knee arthroplasty: an analysis of 56,216 knees. J Bone Joint Surgery Am 95:775-782. http://dx.doi.org/10.2106/JBJS.L.00211.
35. Higgins JPT, Green S (ed). 2011. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration, London, United Kingdom.
36. Pittler MH, Abbot NC, Harkness E.F., Ernst E. 2000. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 53:485-489. http://dx.doi.org/10.1016/S0895-4356(99)00220-6.
37. Vickers A, Goyal N, Harland R., Rees R. 1998. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 19:159-166.
38. Hedges LV, Olkin I. 1985. Statistical methods for meta-analysis, 1st ed. Academic Press, New York, NY.
39. Yuan Y, Little RJ 2009. Meta-analysis of studies with missing data. Biometrics 65:487-496. http://dx.doi.org/10.1111/j.1541-0420.2008.01068.x.
40. Song F, Parekh S, Hooper L., Loke YK, Ryder J, Sutton AJ, Kwok C.S., Pang C., Harvey I. 2010. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 14: 1-193.
41. Fletcher N, Sofianos D, Berkes M.S., Obremskey WT. 2007. Prevention of perioperative infection. J Bone Joint Surg Am 89:1605-1618. http://dx.doi.org/10.2106/JBJS.F.00901.
42. Josefsson G, Lindberg L, Wicklander B. 1981. Systemic antibiotics and gentamicin-containing bone cement in the prophylaxis of postoperative infections in total hip arthroplasty. Clin Orthop Relat Res 159:194-200.
43. Ritter MA, Campbell E, Keating E.M., Faris PM. 1989. Comparison of intraoperative versus 24 hour antibiotic prophylaxis in total joint replacement. A controlled prospective study. Orthop Rev 18:694-696.
44. Schulitz KP, Winkelman W, Schoening B. 1980. The prophylactic use of antibiotics in alloarthroplasty of the hip joint for coxarthrosis. Arch Orthop Trauma Surg 96:79-82. http://dx.doi.org/10.1007/BF00433285.
45. Soave R, Hirsch JC, Salvati E.A., Brause BD, Roberts RB. 1986. Comparison of ceforanide and cephalothin prophylaxis in patients undergoing total joint arthroplasty. Orthopedics 9:1657-1660.
46. Vainionpää S, Wilppula E, Lalla M, Renkonen OV, Rokkanen P. 1988. Cefamandole and isoxazolyl penicillins in antibiotic prophylaxis of patients undergoing total hip or knee joint arthroplasty. Arch Orthop Trauma Surg 107:228-230. http://dx.doi.org/10.1007/BF00449674.
47. Davis WA, Kane JG 1987. Antimicrobial prophylaxis for arthroplasty: a comparative study of cefonicid and cefazolin. Orthopedics 10:1405-1409.
48. Pollard JP, Hughes SPF, Scott JE, Evans M.J., Benson MKD. 1979. Antibiotic prophylaxis in total hip replacement. Br Med J 1:707-709. http://dx.doi.org/10.1136/bmj.1.6165.707.
49. Hill C, Flamant R, Mazas R., Evrard J. 1981. Prophylactic cefazolin versus placebo in total hip replacement. Lancet 317 (8224):795-797.
50. Jones RN, Wojeski W, Bakke J., Porter C, Searles M. 1987. Antibiotic prophylaxis of 1,036 patients undergoing elective surgical procedures: a prospective randomized comparative trial of cefazolin, cefoxitin, and cefotaxime in a prepaid medical practice. Am J Surg 153:341-346. http://dx.doi.org/10.1016/0002-9610(87)90573-3.
51. Ericson C, Lidgren L, Lingberg L. 1973. Cloxacillin in the prophylaxis of postoperative infections of the hip. J Bone Joint Surg Am 55:808-813.
52. Richardson JB, Roberts A, Robertson JFR, John PJ, Sweeney G. 1993. Timing of antibiotic administration in knee replacement under tourniquet. J Bone Joint Surg Br 75:32-35.
53. Mauerhan DR, Nelson CL, Smith D.L., Fitzgerald RH, Slama TG, Petty RW, Jones R.D., Evans RP. 1994. Prophylaxis against infection in total joint arthroplasty. J Bone Joint Surg Am 76:39-45.
54. Suter F, Avai A, Fusco U., Gerundini M, Caprioli S, Maggiolo F. 1994. Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. Eur J Clin Microbiol Infect Dis 13:793-796. http://dx.doi.org/10.1007/BF02111338.
55. Scaglione F, De Martini G, Peretto L, Ghezzi R., Baratelli M, Arcidiancono MM, Fraschini F. 1997. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Antimicrob Agents Chemother 41:2292-2294.
56. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, Bogaers-Horman D, de Baere GAJ, Sturrman A, van Belkum A, Kluytmans JAJW. 2002. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebocontrolled study. Clin Infect Dis 35:353-358. http://dx.doi.org/10.1086/341025.
57. Jacobson C, Osmon DR, Hanssen A, Trousdale R.T., Pagnano MR, Pyrek J, Berbari E, Naessens J. 2005. Prevention of wound contamination using DuraPrep solution plus Ioban 2 drapes. Clin Orthop Relat Res 439:32-37. http://dx.doi.org/10.1097/01.blo.0000182245.29830.bc.
58. Soriano A, Bori G, García-Ramiro S, Martinez-Pastor JC, Miarna T, Codina C, Maculé F, Basora M, Martínez JA, Riba J, Suso S, Mensa J. 2008. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis 46:1009-1014. http://dx.doi.org/10.1086/529145.
59. Tyllianakis ME, Klarageorgos AC, Marangos M.N., Saridis AG, Lambiris EE. 2010. Antiobiotic prophylaxis in primary hip and knee arthroplasty: comparison between cefuroxime and two specific antistaphylococcal agents. J Arthroplasty 25:1078-1082. http://dx.doi.org/10.1016/j.arth.2010.01.105.
60. Chareancholvanich K, Udomkiat P, Waikukul S. 2012. A randomized controlled trial between fosfomycin and cefuroxime as the antibiotic prophylaxis in knee arthroplasty. J Med Assoc Thai 95(Suppl):S6-S13.
61. van Rijen MML, Bode LGM, Baak DA, Kluytmans JAJW, Vos MC. 2012. Reduced costs for Staphylococcus aureus carriers treated prophylactically with mupirocin and chlorhexidineincardiothoracic and orthopedic surgery. PLoS One 7(8):e43065. http://dx.doi.org/10.1371/journal.pone.0043065.
62. Hinarejos P, Guirro P, Leal J., Montserrat F, Pelfort X, Sorli M.L., Horcajada JP, Ping L. 2013. The use of erythromycin and colistinloaded cementin total knee arthroplasty does not reduce the incidence of infection. J Bone Joint Surg Am 95:769-774. http://dx.doi.org/10.2106/JBJS.L.00901.
63. Morrison TN, Taneja M, Purtill J.J., Austin M., Parvizi J. 2014. Prospective, randomized, blinded study to evaluate two surgical skin preparations in reducing SSI after TJA. Abstr 2014 Am Assoc Orthop Surg, abstr 049.
64. Phillips M, Rosenberg A, Shopsin B., Cuff G, Skeete F, Foti A., Kraemer K, Ingluma K, Press R., Bosco J. 2014. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol 35:826-832. http://dx.doi.org/10.1086/676872.
65. De Lalla F., Novelli A, Pellizer G., Milocchi F, Viola F, Rigon A., Stecca C, Dal Pizzol V, Fallani S, Periti P. 1993. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 37:2693-2698. http://dx.doi.org/10.1128/AAC.37.12.2693.
66. DeBenedictis KJ, Rowan NM, Boyer BL 1984. A double blind study comparing cefonicid with cefazolin as prophylaxis in patients undergoing total hip or knee replacement. Rev Infect Dis 6(Suppl):S901-S904.
67. Evard J, Doyon F, Acar J.F., Salord JC, Mazas F, Flamant R. 1988. Two-day cefamandole versus five-day cephazolin prophylaxis in 965 total hip replacements. Int Orthop 12:69-73.
68. Friedman RJ, Friedrich LV, White R.L., Kays MB, Brundage DM, Graham J. 1990. Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty. Clinical Orthop Relat Res 260:17-23.
69. Gunst JP, Deletang S, Rogez J.M., Blanloeil Y., Baron D, Dixneuf B. 1984. Prophylactic antibiotic therapy with cefamandole in total hip surgery replacement using Charnley's tent. A randomized study. Pathol Biol (Paris) 32:567-569. (In French.)
70. McQueen MM, Hughes SP, May P, Verity L. 1990. Cefuroxime in total joint arthroplasty. J Arthroplasty 5:169-172. http://dx.doi.org/10.1016/S0883-5403(06)80236-6.
71. Wymenga A, van Horn J, Theeuwes A, Muytjens H., Slooff T. 1992. Cefuroxime for prevention of postoperative coxitis. Acta Orthop Scand 63(1):19-24. http://dx.doi.org/10.3109/17453679209154842.
72. Johnson DP. 1987. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Joint Surg Br 69:787-789.
73. Meehan J, Jamali AA, Nguyen H. 2009. Current concepts review. Prophylactic antibiotics in hip and knee arthroplasty. J Bone Joint Surg Am 91:2480-2490.
74. Parvizi J, Saleh KJ, Ragland P.S., Pour AE, Mont MA. 2008. Efficacy of antibiotic-impregnated cement in total hip arthroplasty. A meta-analysis. Acta Orthop 79:335-341. http://dx.doi.org/10.1080/17453670710015229.
75. Chiu FY, Lin C-FJ, Chen CM, Lo W.H., Chaung T-Y. 2001. Cefuroximeimpregnated cement at primary total knee arthroplasty in diabetes mellitus. J Bone Joint Surg Br 83:691-695. http://dx.doi.org/10.1302/0301-620X.83B5.11737.
76. Chiu F-Y, Chen C-M, Lin C-FJ, Lo WH. 2002. Cefuroximeimpregnated cement in primary total knee arthroplasty. J Bone Joint Surg Am 84:759-762.
77. Nelson CL, Green TG, Porter R.A., Warren RD. 1983. One day versus seven days of preventive antibiotic therapy in orthopedic surgery. Clin Orthop Relat Res 176:258-263.
78. Bryan CS, Morgan SL, Caton R.J., Lunceford EM. 1988. Cefazolin versus cefamandole for prophylaxis during total joint arthroplasty. Clin Orthop Relat Res 228:117-122.
79. Jones RN, Slepack JM, Wojeski WV 1988. Cefotaxime single-dose surgical prophylaxis in a prepaid group practice. Comparisons with other cephalosporins and ticarcillin/clavulanic acid. Drugs 35(Suppl): 116-123.
80. Liebergall M, Mosheiff R, Rand N., Peyser A, Shaul J, Kahane Y., Shapiro M. 1995. A double-blinded, randomized, controlled trial to compare cefazolin and cefonicid for antimicrobial prophylaxis in clean orthopedic surgery. Isr J Med Sci 31:62-64.
81. Mollan RA, Haddock M, Webb CH 1992. Teicoplanin versus cephamandole for antimicrobial prophylaxis in prosthetic joint implant surgery: preliminary results. Eur J Surg Suppl 567:19-21.
82. Periti P, Stringa G, Donati L., Mazzei T, Mini E, Novelli A. 1994. Teicoplanin - its role as systemic therapy of burn infections and as prophylaxis for orthopedic surgery. Italian study groups for antimicrobial prophylaxisin orthopaedic surgery and burns. Eur J Surg Suppl 567:3-8.
83. Petiri P, Stringa G, Mini E. 1999. Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic implant surgery. Eur J Clin Microbiol Infect Dis 18:113-119. http://dx.doi.org/10.1007/s100960050238.
84. van den Brand IC, Castelein RM. 2001. Total joint arthroplasty and incidence of postoperative bacteriuria with and indwelling catheter or intermittent catheterization with one-dose antibiotic prophylaxis. J Arthroplasty 16:850-855. http://dx.doi.org/10.1054/arth.2001.25547.
85. Wall R, Klenerman L, McCullough C., Fyfe I. 1988. A comparison of teicoplanin and cefuroxime as prophylaxis for orthopedic implant surgery: a preliminary report. JAntimicrob Chemother 21(Suppl):141-146. http://dx.doi.org/10.1093/jac/21.suppl-A.141.
86. Winter M, Ungemach J, Glicksman H. 1987. Flucloxacillin and ceftriaxone in the perioperative prophylaxis of patients undergoing hip and knee surgery by a prospective randomized trial. Chemiotherapia 6(Suppl):577.
87. Gilliam DL, Nelson CL 1990. Comparison of a one-step iodophor skin preparation versus traditional preparation in total joint surgery. Clin Orthop Relat Res 250:258-260.
88. Zdeblick TA, Lederman MM, Jacobs M.R., Marcus RE. 1986. Preoperative use of povidone-iodine. A prospective, randomized study. Clin Orthop Relat Res 213:211-215.
89. Crowninshield RD, Rosenberg AG, Sporer SM 2006. Changing demographics of patients with total joint replacement. Clin Orthop Relat Res 443:266-272. http://dx.doi.org/10.1097/01.blo.0000188066.01833.4f.
90. Centers for Disease Control and Prevention. 2014. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
91. Shorr AF. 2007. Epidemiology of staphylococcal resistance. Clin Infect Dis 45(Suppl):S171-S176. http://dx.doi.org/10.1086/519473.
92. Wisplinghoff H, Bischoff T, Tallent S.M., Seifert H., Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
93. Kallen AJ, Mu Y, Bulens S., Reingold A, Petit S, Gershman K., Ray SM, Harrison LH, Lynfield R, Dumyati G., Towns JM, Schaffner W, Patel PR, Fridkin SK 2010. Health care-associated invasive MRSA infections, 2005-2008. JAMA 304:641-648. http://dx.doi.org/10.1001/jama.2010.1115.
94. Greene LR, Mills R, Noss R., Sposato K, Vignari M. 2010. Guide to the elimination of orthopedic surgical site infections. http://apic.org/Professional-Practice/Implementation-guides. Accessed 26 November 2014.
95. Aureden K, Arias K, Burns L.A., Creen C., Hickok J, Moody J, Orioa S., Risa K. 2010. Guide to the elimination of methicillin-resistant Staphylococcus aureus (MRSA) transmission in hospital settings, 2nd ed. http://apic.org/Professional-Practice/Implementation-guides. Accessed 26 November 2014.
96. Espehaug B, Engesaeter LB, Vollset S.E., Havelin LI, Langeland N. 1997. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg Br 79:590-595.
97. Lieberman IH, Moran E, Hastings D.E., Bogach ER. 1994. Heterotopic ossification after primary cemented and noncemented total hip arthroplastyin patients with osteoarthritis and rheumatoid arthritis. CanJ Surg 37:135-139.
98. Lynch M, Esser MP, Shelley P, Wroblewski BM 1987. Deep infection in Charnley low-friction arthroplasty. J Bone Joint Surg Br 69:355-360.
99. Josefsson G, Gudmundsson G, Kolmert L., Wijkström S. 1990. Prophylaxis with systemic antibiotics versus gentamicin bone cement in total hip arthroplasty. A five-year survey of 1688 hips. Clin Orthop Relat Res 253:173-178.
100. Josefsson G, Kolmert L. 1993. Prophylaxis with systemic antibiotics versus gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1,688 hips. Clin Orthop Relat Res 292:210-214.
101. Centers for Disease Control/National Healthcare Safety Network. 2015. CDC/NHSN surveillance definitions for specific types of infections. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef-current.pdf. Accessed 7 June 2015.